The goal of this work package will be to characterise in depth the back-up anti-HCV MAb by
Assessing the capacity of the back-up anti-HCV MAb to neutralise pseudotype viruses (HCVpp) representing diverse HCV genotypes
Assessing the capacity of the back-up anti-HCV MAb to neutralize infectioous clones of HCV (HCVcc)
Evaluating the E1E2-binding affinity of the back-up anti-HCV MAb
Mapping the E1E2-epitope(s) recognized by the back-up anti-HCV MAb
Sequencing the variable regions of the heavy and light chains of the back-up anti-HCV MAb
Determine the in vitro and in vivo neutralizing activity of the humanised antibody